Board Change • May 01
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Steve Picton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 24
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Steve Picton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공지 • Nov 25
Echo IQ Limited Completes its Clinical Validation for its Heart Failure Clinical Decision Support Software in Collaboration with the Mayo Clinic Platform Echo IQ Limited announced that it has completed its clinical validation for its heart failure clinical decision support software ("EchoSolv HF") in collaboration with the Mayo Clinic Platform ("MCP"), a division of the Mayo Clinic, a top ranked US hospital. The MCP Validate program is a unique in-market AI evaluation program which generates an independent and objective report on accuracy, efficacy and susceptibility to bias for AI-based decision software. The clinical validation was designed to evaluate the EchoSolv HF model's ability to detect heart failure on an independent dataset of ~17,000 individual echocardiogram studies. In a major milestone, the primary endpoint of the clinical validation has been met, with results exceeding expectations. The study results show that EchoSolv HF demonstrated outstanding performance in identifying patients with heart failure, achieving a sensitivity of 99.5%. Likewise, the model was accurate in identifying patient that did not have heart failure, achieving a specificity of 91.0%. Completion of the clinical validation marks the final clinical requirement prior to a formal submission for clearance by the US Food & Drug Administration ("FDA"). Echo IQ is now in the process of completing its formal submission to advance the clearance of EchoSolv HF via the FDA's 510(k) regulatory pathway. The Company expects to lodge this submission in the coming weeks. FDA clearance of the solution would allow for EchoSolv HF to be marketed to and used by healthcare professionals in the USA as a clinical decision support software to aid in the detection of heart failure. Heart failure is the leading cause for rehospitalisation in the US and accounts for 17% of all healthcare expenditure in the country. It is now estimated that one in four Americans will develop heart failure in their lifetime. Upon potential FDA clearance of the solution, the Company intends to leverage its existing footprint in the US market to drive uptake of EchoSolv HF. 공지 • Nov 13
Echo Iq Highlights Market Potential for Echosolv as Following Presentation of New Data for Severe Aortic Stenosis (As) Presented At Aha Scientific Sessions 2025 Echo IQ announced that overwhelmingly convincing data from two recent studies have highlighted the significant gaps in the current standard-of-care for diagnosing and monitoring severe aortic stenosis (AS), and potential for EchoSolv AS to drive improved patient outcomes. The results from both studies were presented separately at the American Heart Association (AHA) Scientific Sessions 2025, which was held in New Orleans, Louisiana. A key takeaway from the study that reviewed echocardiograms for more than 1.2 million patients is that the 'watchful waiting' strategy for moderate-to-severe AS cases is failing many of these patients. In addition, the insights from the results that show how EchoSolv AS was able to identify the severe AS phenotype more accurately than cardiologists, particularly in some subtypes of AS. This study was of particular interest as it showed clearly that the company have work to do in accurately diagnosing women with aortic stenosis and the company are optimistic with the performance of EchoSolv AS to improve the gender equity. Study titled, "Accuracy of cardiologist reporting of severe aortic stenosis vs decision-support artificial intelligence and its impact on clinical management" presented by Dr. Vikas Bhat, University of Notre Dame Australia, this investigator-initiated study compared traditional cardiologist reporting with EchoSolv™?, an AI-powered clinical decision support system. Findings from 30,878 echocardiograms revealed: EchoSolv outperformed cardiologists in identifying severe AS phenotypes, particularly in women and low- gradient cases. Findings underscore the need for policy and clinical practice changes to address treatment gaps and improve survival. This study was funded by an IIS grant from Edwards LifeScience. The funders played no part in the data curation/analysis /preparation of these data. EchoSolv AS is poised to change this paradigm by enabling more precise and consistent identification of high-risk AS patients, thereby supporting clinicians in making informed, timely decisions regarding intervention. Globally, AS is a widespread but frequently underdiagnosed condition, primarily caused by calcification of the aortic valve, which serves as a critical gateway to the heart. Failure to diagnose AS in a timely manner can lead to missed opportunities for lifesaving interventions, such as valve replacement surgery. EchoSolv AS has undergone rigorous validation, including FDA Clearance, through extensive testing across both the United States and Australia, demonstrating the utility of aiding in the accurate diagnosis of patients with aortic stenosis. NEDA principal investigator, Professor David Playford, the senior author for both studies, said: " These studies confirm previous reports in two ways. First, reaffirm that moderate and severe aortic stenosis is a lifethreatening condition that causes significant health service utilization, heart failure hospitalizations and premium mortality. Second, artificial intelligence is capable of outperforming cardiologists in the identification of the set of abnormalities that happen when aortic stenosis progresses toward the severe state. These two findings, taken together, reinforce that EchoSolv AS AI should be considered as a routine option during echocardiographic reporting. Authorised for release by the Board of Directors of Echo IQ Limited. 공지 • Sep 30
Echo IQ Limited, Annual General Meeting, Nov 18, 2025 Echo IQ Limited, Annual General Meeting, Nov 18, 2025. Breakeven Date Change • Aug 31
Forecast breakeven date pushed back to 2027 The 2 analysts covering Echo IQ previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 83% to 2026. The company is expected to make a profit of AU$44.4m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule. 
